Atrial fibrillation
Conditions
Interventions
Determine the initial dose by the genotype-based algorithm (intervention group)
Initiation of warfarin treatment at 1.5 mg/day. (control group)
Sponsors
Hyogo University of Health Sciences
Osaka City University Hyogo College of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who will take warfarin. 2) Patients who are 20-80 years old. 3) Patients who will voluntarily give written an informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients who have taken warfarin before. 2) Patients who urgently have to start anti-coagulant therapy. 3) Patients with a history of the prosthetic valve replacement. 4) Patients for whom target INR 2.0-3.0 are inadequate. 5) Patients with a severe hepatic or renal disorder. 6) Patients with thyroid dysfunction. 7) Patients who are applicable to contraindication to warfarin therapy. 8) Patients who take medicines that interact with warfarin. 9) Patients who cannot understand or practice the dietary instruction. 10) Patients judged by investigators as ineligible for study enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration required for determination of stable maintenance dose. (The number of visits to the hospital and the changes in dose from initial to final dose until reaching the target INR (1.8 to 3.0) for the second time in a row.) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)The bleeding events or thromboembolic events. 2)Any other adverse clinical events. 3)The number of adjustment of warfarin dose. | — |
Countries
Japan
Contacts
Public ContactShinpei Nonen
Hyogo University of Health Science School of Pharmacy
Outcome results
None listed